(Q36150652)

12 August 2017

1 reference

title

Emerging drugs for ovarian cancer. (English)

1 reference

12 August 2017

1 reference

Lloyd R Kelland

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

413-424

1 reference

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Oral altretamine used as salvage therapy in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Role of pegylated liposomal doxorubicin in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Review of the use of topotecan in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Ovarian cancer: strategies for overcoming resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.413

10.1517/14728214.10.2.413

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference